Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
Degenerative Neurological and Neuromuscular Disease · 2017
DOI: 10.2147/dnnd.s135748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Degenerative Neurological and Neuromuscular Disease, 2017. Verfasst von Michael Hinchcliffe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Paracelsis Ltd, mh@paracelsis.com. Die Arbeit wurde bisher 64-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Paracelsis Ltd, mh@paracelsis.com.
- PharmaSci Consulting Ltd, Nottingham, UK.
Zitieren
APA
Hinchcliffe, M., & Smith, A. (2017). Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degenerative Neurological and Neuromuscular Disease. https://doi.org/10.2147/dnnd.s135748
Vancouver
Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degenerative Neurological and Neuromuscular Disease. 2017. doi:10.2147/dnnd.s135748
BibTeX
@article{Hinchcliffe2017,
author = {Hinchcliffe, Michael and Smith, Alan},
title = {Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis},
journal = {Degenerative Neurological and Neuromuscular Disease},
year = {2017},
doi = {10.2147/dnnd.s135748}
}
EUVIMED